Zacks Investment Research Upgrades Collegium Pharmaceutical Inc. (COLL) to “Hold”
Collegium Pharmaceutical Inc. (NASDAQ:COLL) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a note issued to investors on Wednesday.
According to Zacks, “Collegium Pharmaceutical Inc. is a specialty pharmaceutical company. It develops and commercializes prescription and over-the-counter pharmaceuticals for the treatment of central nervous system, respiratory and skin related disorders. The Company’s product candidate consists of COL-195, COL-196, COL-171, COL-003 and COL-172 which are in different clinical trial. It developed a formulation platform technology, DETERx, for the treatment of chronic pain. Collegium Pharmaceutical Inc. is based in CUMBERLAND, United States. “
Other analysts have also recently issued research reports about the company. Jefferies Group reissued a “buy” rating on shares of Collegium Pharmaceutical in a research report on Thursday, September 22nd. Needham & Company LLC reaffirmed a “buy” rating and set a $30.00 price target on shares of Collegium Pharmaceutical in a research report on Wednesday, September 14th. Gabelli assumed coverage on Collegium Pharmaceutical in a research report on Tuesday, September 13th. They set a “buy” rating and a $25.00 price target for the company. Finally, Piper Jaffray Cos. set a $23.00 price target on Collegium Pharmaceutical and gave the stock a “buy” rating in a research report on Thursday, August 11th. One investment analyst has rated the stock with a hold rating and six have given a buy rating to the company. The stock presently has an average rating of “Buy” and an average target price of $27.60.
This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at https://www.americanbankingnews.com/2016/10/12/zacks-investment-research-upgrades-collegium-pharmaceutical-inc-coll-to-hold.html
Shares of Collegium Pharmaceutical (NASDAQ:COLL) traded up 3.00% during trading on Wednesday, reaching $18.19. The company’s stock had a trading volume of 378,623 shares. The company has a 50 day moving average of $13.10 and a 200-day moving average of $14.51. Collegium Pharmaceutical has a 12-month low of $8.24 and a 12-month high of $30.58. The stock’s market cap is $427.97 million.
Collegium Pharmaceutical (NASDAQ:COLL) last posted its quarterly earnings data on Wednesday, August 10th. The specialty pharmaceutical company reported ($1.05) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.76) by $0.29. Analysts forecast that Collegium Pharmaceutical will post ($3.86) EPS for the current year.
In related news, Director John A. Fallon acquired 2,375 shares of Collegium Pharmaceutical stock in a transaction on Friday, August 12th. The stock was acquired at an average price of $10.59 per share, for a total transaction of $25,151.25. Following the purchase, the director now owns 2,375 shares of the company’s stock, valued at approximately $25,151.25. The acquisition was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Company insiders own 37.93% of the company’s stock.
Several institutional investors have recently added to or reduced their stakes in COLL. Royal Bank of Canada raised its position in Collegium Pharmaceutical by 2.7% in the second quarter. Royal Bank of Canada now owns 11,600 shares of the specialty pharmaceutical company’s stock worth $137,000 after buying an additional 300 shares during the last quarter. Schwab Charles Investment Management Inc. bought a new position in Collegium Pharmaceutical during the second quarter worth $253,000. Highbridge Capital Management LLC bought a new position in Collegium Pharmaceutical during the second quarter worth $166,000. Sabby Management LLC raised its position in Collegium Pharmaceutical by 23.5% in the second quarter. Sabby Management LLC now owns 101,410 shares of the specialty pharmaceutical company’s stock worth $1,202,000 after buying an additional 19,310 shares during the last quarter. Finally, A.R.T. Advisors LLC bought a new position in Collegium Pharmaceutical during the second quarter worth $148,000. Institutional investors and hedge funds own 62.13% of the company’s stock.
Collegium Pharmaceutical Company Profile
Collegium Pharmaceutical, Inc is a specialty pharmaceutical company. The Company is developing and planning to commercialize abuse-deterrent products that include its DETERx platform technology for the treatment of chronic pain and other diseases. The Company’s lead product candidate, Xtampza ER (Xtampza) is an abuse-deterrent, extended-release, oral formulation of oxycodone, opioid medication.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Collegium Pharmaceutical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Collegium Pharmaceutical Inc. and related companies with MarketBeat.com's FREE daily email newsletter.